Related Experiment Video

Updated: Feb 17, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K

Oncorine, the World First Oncolytic Virus Medicine and its Update in China

Min Liang1

  • 1Totbiopharm Shanghai R&D Center, 781 Cailun Road, Shanghai, 201203, China.

Current Cancer Drug Targets
|December 1, 2017
PubMed

Insights

Oncolytic virus therapy shows promise for cancer treatment. China

Area of Science:

  • Oncolytic virotherapy
  • Cancer therapeutics
  • Biotechnology

Background:

  • Oncolytic viruses represent a promising new strategy for cancer treatment.
  • Commercial research and development for oncolytic virus products began in China in 1998.
  • The first commercial oncolytic virus, Oncorine (H101), was developed in China.

Purpose of the Study:

  • To review the development of Oncorine (H101) in China.
  • To analyze the Chinese market response to Oncorine's launch.
  • To highlight the success of oncolytic virus commercialization in China.

Main Methods:

  • Phase III clinical trial of Oncorine (H101) for nasopharyngeal carcinoma.
  • Regulatory approval process by the Chinese SFDA.
  • Market launch and post-launch analysis.

Main Results:

  • Oncorine (H101) was approved by the Chinese SFDA in November 2005 for nasopharyngeal carcinoma in combination with chemotherapy.
  • Oncorine (H101) acquired GMP certification in August 2006.
  • The Chinese market demonstrated a response to the launch of this novel oncolytic virus therapy.

Conclusions:

  • Oncolytic virus therapy, exemplified by Oncorine, has been successfully developed and commercialized in China.
  • The development and market introduction of Oncorine signify a milestone in China's biopharmaceutical industry.
  • The Chinese market's reception of Oncorine provides insights into the potential of oncolytic virus therapeutics.
Keywords:
Oncorinecancerchemotherapynasopharyngeal carcinomaoncolytic virusvirotherapy

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.4K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K